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esponsibility of InstAbstract A rapid, speciﬁc and sensitive HPLC–MS/MS method was developed and validated for the
determination of 20(S)-protopanaxadiol (PPD) in human plasma. PPD and the internal standard PD were
extracted from plasma by liquid–liquid extraction with cyclohexane–methylene dichloride (2:1, v/v). The
separation was performed on a HyPURIYTY C18 column using methanol–5 mM ammonium formate
(90:10, v/v) as mobile phase at a ﬂow rate of 0.35 mL/min. Mass spectrometric detection was carried out
by electrospray ionization (ESI) in the positive ion mode using multiple reaction monitoring (MRM). The
monitored transitions were m/z 425.4-217.2 for PPD and at m/z 461.4-425.5 for PD. The method was
linear over the range 0.512–100 ng/mL with a lower limit of quantiﬁcation (LLOQ) of 0.512 ng/mL. The
mean extraction recovery of PPD was greater than 78.2% and no signiﬁcant matrix effect was detected.
The intra- and inter-day precisions were less than 10% and the biases below 4% for PPD. The validated
method was applied to a three-level single-dose clinical pharmacokinetics study of 12 healthy Chinese
volunteers and the main pharmacokinetic parameters of PPD were obtained.
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Ginseng has been widely used as a Chinese medicinal herb for
thousands of years because of its extensive medical value. One of
the clinical indications for ginseng is antidepression and anti-
anxiety according to traditional Chinese medicine theory. Also,
ginseng is widely used in western world for mood improvement1.
It is generally considered that ginsenosides extracted from ginseng
are the major bioactive compounds2–4. 20(S)-Protopanaxadiol
(PPD, dammar-24-ene-3β, 12β, 20(S)-triol) is the main metabolite
of protopanoxadiol type ginsenosides such as Rb1, Rg3 and Rh25–8.
Though antidepressants for the treatment of major depression are
widely available, many of them are proved not so effective clinically9.
In addition, side effects of these medications are common and could be
severe in some cases10–12. Thus, it is necessary to ﬁnd more effective
antidepressants with fewer side effects. In previous preclinical studies,
antidepressant-like activity of PPD given per oral was measured in
animal models, including tail suspension test, forced swimming test
and rat olfactory bulbectomy depression model. In all those tests, PPD
demonstrated antidepressive-like effect which was equal to or better
than that of ﬂuoxetine4. Moreover, in our preclinical acute toxicity test,
it was demonstrated that the maximum oral dose in Sprague-Dawley
rats and beagle dogs was 12.0 and 3.18 g/kg which were respectively
equivalent to 1888- and 500-fold of the clinical dosage proposed. In the
long-term toxicity experiments, after oral administration of PPD in
Sprague-Dawley rats (63.56, 200.85 and 635.60 mg/kg) for 3 months,
no obvious adverse events and drug-induced pathological damages
were observed, indicating that PPD was well tolerated. Actually, PPD
is a promising drug candidate for the treatment of depression and
currently undergoing clinical trials in China.
The preclinical pharmacokinetics of PPD showed that the oral
bioavailability of PPD is low (31.0% in rats and 9.6% in dogs) due
to its metabolism in the gastrointestinal tract13. To determine PPD
in biological samples, several HPLC/MS-MS methods have been
reported for the quantitative analysis of PPD extracted from
biological samples, such as in rat plasma7,14–16 and in dog
plasma17. But these methods suffered from long analysis time
due to simultaneous determination of PPD with its parent ginseno-
sides and most were not sensitive enough to determine PPD in
human plasma. Although a method was established to determine
PPD in human plasma18, this method involved a chromatographic
separation using a high mobile phase ﬂow rate (1.3 mL/min) and a
large sample injection volume (40 mL), which could be further
developed in terms of cost-effective and environmentally friendly.
So, a more rapid and sensitive analytic method for the determina-
tion of PPD was needed for further study of clinical pharmaco-
kinetics of PPD in human plasma.
In the present study, a new simple and sensitive HPLC–ESI-
MS/MS method for the determination of PPD in human plasma
was developed, optimized and validated. In order to deﬁne
comprehensive pharmacokinetic characteristics and proﬁles of
PPD in human, this method was applied to a clinical pharmaco-
kinetic study involving three-level single-dose oral administration
of PPD in healthy Chinese volunteers.Figure 1 Chemical structures of (A) 20(S)-protopanaxadiol and (B)
panoxadiol (IS).2. Material and methods
2.1. Chemicals and reagents
PPD (purity 99.8% by HPLC) and internal standard (IS) panox-
adiol (PD, purity 99.8% by HPLC) were purchased from theNational Institutes for Food and Drug Control (Beijing, China).
The chemical structures of the two compounds are shown in
Fig. 1. The PPD capsules used in the pharmacokinetic study were
produced and supplied by Xin Sheng Yuan Co., Ltd. (Shanghai,
China). Methanol was of HPLC grade (Tedia, USA). Cyclohex-
ane, methylene dichloride, ammonium formate and the other
reagents were of analytical grade. Deionized water was freshly
processed through a Milli-Q water puriﬁcation system (Millipore,
USA). Blank human plasma was collected from healthy volunteers
who signed on the written informed consent and received the same
clinical screening procedure by the researchers.
2.2. Instrumentation and HPLC–MS/MS conditions
Analysis was performed on an Agilent 6410B triple quadrupole
LC–MS system (Agilent, Germany) equipped with an electrospray
ionization source (ESI) and Agilent MassHunter Workstation
Software data processing system.
Chromatographic separation was carried out on a Thermo
HyPURIYTY C18 column (150 mm 2.1 mm, 5 μm, Thermo,
USA) with a Gemini C18 guard column (4 mm 3.0 mm,
Phenomenex, USA). The mobile phase consisted of methanol–
5 mM ammonium formate (90:10, v/v) at a ﬂow rate of 0.35 mL/
min. The injection volume was 10 mL and the column temperature
was maintained at 40 1C.
The mass spectrometer was operated in positive ion mode using
multiple reaction monitoring (MRM). The precursor-product ion
transitions were monitored at m/z 425.4-217.2 for PPD and m/z
461.4-425.5 for PD. The optimized MS/MS parameters were as
follows: fragmentor voltage 120 V, collision energy (CE) 10 eV
for PPD and 20 eV for PD, source temperature 300 1C, drying gas
(N2) ﬂow 8 L/min, nebulizer pressure 50 psi and capillary voltage
4 kV.
2.3. Calibration standards and quality control samples
The stock solution of PPD (1 mg/mL) and IS (1 mg/mL) were both
freshly prepared in methanol and stored at 4 1C. The IS working
solution was prepared by diluting the IS stock solution to a
concentration of 6 ng/mL with methanol before use.
Standard working solutions of PPD were prepared by even-
tually diluting the stock solution with methanol to seven different
concentration levels (1000, 400,160, 64, 25.6, 10.24 and 5.12 ng/
mL). 50 mL of these standard solutions was added into a clean
10 mL glass tube and evaporated to dryness under a gentle stream
of nitrogen at 40 1C, and then 500 μL of blank plasma was added
and vortex-mixed for 3 min to prepare calibration standard
samples with concentration levels of 100, 40, 16, 6.4, 2.56,
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prepared independently in the same way at three concentration
levels (1.024, 6.4 and 80 ng/mL).
2.4. Sample preparation
500 mL plasma sample was transferred to a glass tube following which
50 mL IS working solution (6 ng/mL) and 50 mL 30% potassium
carbonate solution were added. After vortex-mixing for 30 s, 4 mL
cyclohexane–methylene dichloride (2:1, v/v) was added. The mixture
was vortexed for 3 min and centrifuged at 440 g for 5 min. 3 mL of
the organic phase was transferred to a clean tube and evaporated to
dryness under a gentle stream of nitrogen at 40 1C. The residue was
reconstituted by 100 μL mobile phase, and the remained undissolvable
fraction was centrifuged off at 15,700 g for 5 min. Then 10 μL of
the supernatant was injected into the chromatographic system.
2.5. Method validation
2.5.1. Speciﬁcity
Speciﬁcity was assessed by comparing the chromatogram of
extracted blank plasma from six individual healthy volunteers
with the corresponding plasma samples spiked with IS and PPD.
The typical clinical samples from different subjects after oral
administration of 100 mg PPD for 1 h was also analyzed to check
for the endogenous interference.
2.5.2. Linearity and LLOQ
Linearity was tested at seven levels of concentrations covering the
range 0.512–100 ng/mL. Calibration curves were established by
plotting the peak area ratios of PPD to IS versus PPD concentra-
tions in the calibration standard samples. The regression para-
meters were calculated by linear least square regression (1/C2
weighing). The accuracy of back-calculated values for seven
individual points must be within 85%–115% of the theoretical
concentration. The LLOQ was deﬁned as the lowest concentration
on the calibration curve at which precision was within 20% and
accuracy was within 80%–120%, and the signal-to-noise ratio at
this concentration was at least 10.
2.5.3. Accuracy and precision
The accuracy and precision of the method were assessed by
determining QC samples at three concentration levels (1.024, 6.4
and 80 ng/mL) in ﬁve replicates each in three consecutive days.
The concentration of each sample was calculated by the calibration
curve prepared on the same day. The accuracy was determined by
comparing the calculated concentration to its nominal concentra-
tion and expressed as a percentage expected to be within 85%–
115%, and the precision of analyte was expressed using relative
standard deviation (RSD) which should be within 15%.
2.5.4. Matrix effect and recovery
To evaluate the matrix effects, blank human plasma samples were
processed according to the sample preparation procedure described
above and then spiked with PPD and IS at the ﬁnal concentration
after extraction (1.024, 6.4 and 80 ng/mL). The matrix effect of the
plasma were expressed as the ratio of mean peak area of analyte
spiked post-extraction to that of the neat standard solution in mobile
phase at corresponding concentrations. Three QC concentrations
were evaluated by analyzing ﬁve samples at each concentration. The
matrix effect could be considered as negligible when the ratio was85%–115%. The extraction recoveries were also determined at the
three QC concentrations by comparing the peak areas of extracted
plasma samples with that of standard solutions without undergoing
extraction procedure at the same nominal concentrations.
2.5.5. Stability
Stability of PPD was evaluated using QC samples in three
replicates under the following conditions: post-preparative stability
was determined under autosampler conditions for over 15 h; short-
term stability was examined at ambient temperature (about 25 1C)
over 4 h; long-term stability was determined at 35 1C for 163
days; and freeze–thaw stability was investigated after three freeze–
thaw cycles (room temperature to 35 1C). In addition, stock
solution stability at room temperature for 8 h and at 4 1C for 45
days was also assessed.
2.6. Pharmacokinetic study
The validated method was applied to a pharmacokinetic study
according to the Declaration of Helsinki for Biomedical and the
rules of good clinical practice (GCP). Twelve healthy Chinese
volunteers (6 males and 6 females, aged 20–27 years and weighing
51–71 kg) were selected for this study after a clinical screening
procedure. It was an open-label, randomized, single-dose (three
doses) and three-way crossover study. Prior to study initiation, the
protocol of this study was approved by the Medical Ethics
Committee of School of Pharmaceutical Sciences of Central South
University (Changsha, China) and written informed consent was
obtained from all participants. All volunteers were randomized to
each of the three sequences in a 1:1:1 ratio using a table of random
numbers and orally given a single-dose of PPD (100, 200 and
400 mg) with a 1-week washout between each dose cycle. Venous
blood samples (5 mL each) were collected in heparin containing
tubes at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 h after
administration. The plasma samples were centrifuged at 3000 g
for 10 min and were stored at 35 1C until analysis.
The values of maximum plasma concentration (Cmax) and time
point of maximum plasma concentration (Tmax) were directly
obtained from experimental observations. The area under the
concentration–time curve from 0 h to the last measurable concen-
tration (AUC0 t) was calculated by the linear trapezoidal method.
The area from the last measured concentration to inﬁnity
(AUCt1) was calculated by dividing the last quantiﬁable plasma
concentration by the elimination rate constant (λz), and the
elimination half-life (t1/2) was calculated from the elimination rate
constant. Time-averaged total body clearance (CL/F) was calcu-
lated as the ratio of the administered dose to AUC01 where the
factor F accounts for bioavailability. The apparent volume of
distribution (Vz/F) was estimated as the ratio of CL/F to λz. The
mean residence time (MRT) was calculated by the deﬁnition of
statistical moment theory. All the pharmacokinetic parameters
were acquired and analyzed by a non-compartmental model
performed on Phoenix WinNonlin 6.1 software.3. Results and discussion
3.1. LC–MS/MS conditions
Based on the chemical structure of PPD, it was evaluated under
positive ionization mode as well as negative ion mode. The
[MþH]þ could not be found in positive ion full scan mode
F. Xie et al.388and [MH] was insufﬁciently sensitive to determine in negative
ionization mode. Moreover, [MþNa]þ, [MþCl] and [MþC
H3COO]
 were also investigated, but there was strong inter-
ference in blank plasma samples. Thus, [M2H2OþH]þ (m/z
425.4) was selected as the precursor ions because of the maximum
intensity with adequate sensitivity to analyze the compound in
positive ion mode using an ESI source. The characteristic product
ions were chosen at m/z 217.2 and 425.5 for the best effect,
namely using the transition of m/z 425.4-217.2 for PPD and
m/z 461.4-425.5 for PD (Fig. 2).
The composition of mobile phase was also optimized. Methanol
was selected for the organic phase because it resulted in higher
response compared with acetonitrile. The aqueous phase compo-
nents such as acetic acid, ammonium acetate and ammonium
formate at different percentages were all investigated. A mobile
phase consisted of methanol–5 mM ammonium formate solution
(90:10, v/v) was chosen at last. Compared to previous publishedFigure 2 Mass spectra for (A) the product ion spectra of 20(S)-protopa
panoxadiol.method18, some conditions were improved in this method, such as
internal standard and HPLC column. Moreover, the present
method employing a ﬂow rate of 0.35 mL/min, which was more
cost-effective and environmentally friendly than previously
reported method.3.2. Sample preparation
To simultaneously obtain suitable recoveries and minimum interference
for the determination of PPD, different sample preparation procedures
were investigated. Initially, the extraction method was performed by
protein precipitation using methanol and acetonitrile, but they resulted
in poor recoveries and low sensitivity. Then liquid–liquid extraction
technique was tried as extracting solvents, including isopropanol–
cyclohexane (5:95, v/v), cyclohexane–methylene dichloride (2:1 and
3:2, v/v) and ethylether. It was found that cyclohexane–methylenenaxadiol under positive ion mode and (B) the product ion spectra of
Figure 3 Representative MRM chromatograms in human plasma: (A) blank plasma; (B) plasma spiked with 20(S)-protopanaxadiol (LLOQ
concentration level, 0.512 ng/mL) and panoxadiol (6 ng/mL) and (C) plasma sample from a healthy volunteer 1 h after oral administration of
100 mg 20(S)-protopanaxadiol.
Determination of 20(S)-protopanaxadiol in human plasma by HPLC-MS/MS 389dichloride (2:1, v/v) gave the highest recovery (about 80%) and no
signiﬁcant interference was observed.3.3. Method validation
Representative chromatograms of blank plasma, spiked human
plasma samples and clinical samples are shown in Fig. 3.
The retention time of PPD and IS were 3.8 and 4.6 min,
respectively. No signiﬁcant interference from endogenous com-
pounds was observed at the retention times of both PPD and IS.The plasma calibration standard curves covering the concentra-
tion range of 0.512–100 ng/mL showed good linearity with
correlation coefﬁcient r40.99. The LLOQ for PPD in plasma
was 0.512 ng/mL on the basis of accuracy within 720% and
precision of 7.1%. The inter-day and intra-day accuracy and
precision were determined using QC samples. The results are
shown in Table 1. All the intra- and inter-day precisions were less
than 10% and all the biases were below 4% for PPD, indicating
that the method presented good accuracy and precision.
The average matrix effects for PPD at the concentration levels
of 1.024, 6.4 and 80 ng/mL were found to be 92.0%, 94.5% and
96.5%, respectively, and 96.7% for IS, which indicates that matrix
Table 1 Inter-day and intra-days accuracy and precision of 20(S)-protopanaxadiol in human plasma.
Nominal concentration
(ng/mL)
Intra-day (n¼5) Inter-day (n¼15)
Measured concentrationa
(ng/mL)
Accuracy (%) Precision (%) Measured concentrationa
(ng/mL)
Accuracy (%) Precision (%)
0.512 0.47770.014 93.1 2.9 0.46870.044 91.4 9.4
1.024 0.97470.067 95.0 7.0 1.01670.099 99.2 9.8
6.4 6.2270.30 97.1 4.8 6.3270.51 98.8 8.1
80 74.874.8 93.6 6.5 77.375.1 96.6 6.7
aData are expressed as mean7SD.
Table 2 Stability of 20(S)-protopanaxadiol in human plasma under various conditions.
Item 1.024 ng/mL 6.4 ng/mL 80 ng/mL
Concentrationa
(ng/mL)
Accuracy
(%)
RSD
(%)
Concentrationa
(ng/mL)
Accuracy
(%)
RSD
(%)
Concentrationa
(ng/mL)
Accuracy
(%)
RSD
(%)
Post-preparative
stability
1.06670.101 104.1 9.5 6.8570.63 107.1 9.3 89.678.2 112 9.2
Short-term
stability
1.12770.140 110.1 10.6 7.1470.60 111.7 8.5 81.672.8 102 3.5
Freeze–thaw
stability
1.01970.091 99.5 8.9 6.0670.51 94.7 8.5 81.578.6 101.9 10.6
Long-term
stability
0.93170.107 90.9 11.6 6.6070.88 103.1 13.4 86.374.7 101.5 5.5
aData are expressed as mean7SD, n¼3.
Figure 4 Mean plasma concentration–time proﬁle of 20(S)-proto-
panaxadiol after single-dose oral administration of 100, 200 and
400 mg capsules to 12 healthy Chinese volunteers. Data are expressed
as the mean7SD.
F. Xie et al.390effects are not an issue in the current method. The mean recoveries
of PPD from human plasma were 78.2%, 85.6% and 84.3% for
concentrations of 1.024, 6.4 and 80 ng/mL, respectively, and
75.2% for IS, showing a satisfactory extraction recovery.
In terms of stability, the results shown in Table 2 indicated that
PPD and IS were stable in human plasma and processed samples
under the conditions described.3.4. Clinical pharmacokinetic study
The validated method was successfully applied to a pharmacokinetic
study of PPD in twelve healthy Chinese volunteers after single-dose oral
administration of PPD capsules (100, 200 and 400 mg). All the subjects
completed the study and were incorporated in the pharmacokinetics
analysis. The average concentration–time proﬁles of PPD in human
plasma are shown in Fig. 4 and the main pharmacokinetic parameters
are listed in Table 3. The concentration–time proﬁles of PPD in human
plasma presented double-peak phenomenon. The possible causes
included the hepatic circulation and the different blood collected time.
Mean PPD Cmax ranged 13.34–51.25 ng/mL for doses 100–400 mg.
The plasma PPD concentrations increased proportionally (deﬁned as
P40.05) and there was no pairwise statistically signiﬁcant differences
among the three doses for Cmax and AUC01 after log-transformed
dose-adjusted, which demonstrated dose-independent pharmacokinetics
for PPD. PPD was well absorbed following oral administration, with
mean Tmax ranging 3.5–4.4 h across the dose range 100–400 mg, while
the mean t1/2 of PPD ranged from 10.6–16.5 h. The values of t1/2 and
Tmax were much longer than that of the previous published results
18.4. Conclusions
A rapid, speciﬁc, cost-effective and environmentally friendly
HPLC–MS/MS method for the determination of PPD in human
plasma was developed and validated. A simple liquid–liquid
extraction method was used for sample preparation which pro-
vided stable recoveries with no signiﬁcant endogenous interfer-
ence. The optimized HPLC performance demonstrated an
acceptable sensitivity with a LLOQ of 0.512 ng/mL and a run
Table 3 Pharmacokinetic parameters of 20(S)-protopanaxadiol after single-dose oral administration of 100, 200 and 400 mg capsules to
12 healthy Chinese volunteers.
Parameter Dose (mg)
100 200 400
Cmax (μg/L) 13.3479.46 25.64715.92 51.25737.81
Tmax (h) 4.472.9 3.571.7 3.972.9
AUC0 t (μg  h/L) 91.62737.68 189.11758.52 350.237130.35
AUC01 (μg  h/L) 115.23769.5 206.06759.71 438.977287.51
t1/2 (h) 12.27710.58 10.6473.45 16.58714.76
CL/F (L/h) 1049.497371.78 1055.167336.53 1139.077441.4
Vz/F (L) 14,853.4579223.47 15,344.5174531.72 22,169.3679049.27
MRT0 t (h) 11.5876.29 12.774.08 14.1374.38
MRT01 (h) 19.27715.32 16.2275.65 23.82720.71
Data are expressed as mean7SD, n¼12.
Determination of 20(S)-protopanaxadiol in human plasma by HPLC-MS/MS 391time less than 6 min. The present method employed a more cost-
effective and environmentally friendly HPLC conditions which
was quite suitable for pharmacokinetic studies involving large
sample size. This method was successfully applied to evaluate the
pharmacokinetic proﬁles of PPD after single oral administration to
healthy Chinese volunteers at three doses of 100, 200 and 400 mg.
The results indicated dose-independent pharmacokinetic character-
istics of PPD and a longer elimination half-life than previously
published studies, which could be helpful for the clinical use
of PPD.
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